Literature DB >> 27486495

Case Report: Cardiac Tumor Resection And Repair With Porcine Xenograft.

Walid K Abu Saleh1, Odeaa Al Jabbari1, Basel Ramlawi2, Brian A Bruckner3, Matthias Loebe4, Michael J Reardon1.   

Abstract

Primary cardiac sarcomas are rare and carry a grave prognosis. Improved survival requires a complete margin negative resection of the tumor. These surgical resections are often large and complex, requiring extensive reconstructive procedures. The appropriate material for cardiac reconstruction is not known. We have used glutaraldehyde-fixed bovine pericardium in our early series but have recently employed the MatriStem(®) Surgical Matrix PSMX membrane (ACell(®), Inc.; Columbia, MD), a unique proprietary urinary bladder matrix derived from porcine urinary bladder with the potential for viability and tissue ingrowth. In our study of six patients at this institution, all six underwent successful surgical resection and repair with the MatriStem acellular porcine urinary bladder membrane (ACell). The postoperative course was uncomplicated in all patients, and they are still alive at this time. An aggressive surgical approach to cardiac tumors can possibly lead to complete resection but often requires reconstruction of the cardiac tissue with a membrane. We were able to achieve acceptable results in our cardiac reconstruction by using the ACell extracellular matrix to reconstruct the defect following tumor resection. Longer-term follow-up in these patients, including imaging studies, will be necessary to demonstrate the durability and integrity of the reconstruction.

Entities:  

Keywords:  ACell; atrium; cardiac reconstruction; cardiac tumor; right ventricle

Mesh:

Year:  2016        PMID: 27486495      PMCID: PMC4969019          DOI: 10.14797/mdcj-12-2-116

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN: 1947-6108


  12 in total

1.  Malignant tumor overview.

Authors:  Michael J Reardon
Journal:  Methodist Debakey Cardiovasc J       Date:  2010 Jul-Sep

2.  Primary cardiac sarcomas.

Authors:  J B Putnam; M S Sweeney; R Colon; L A Lanza; O H Frazier; D A Cooley
Journal:  Ann Thorac Surg       Date:  1991-06       Impact factor: 4.330

3.  Surgical Treatment of Primary Cardiac Sarcomas: Review of a Single-Institution Experience.

Authors:  Basel Ramlawi; Monika J Leja; Walid K Abu Saleh; Odeaa Al Jabbari; Robert Benjamin; Vinod Ravi; Oz M Shapira; Shanda H Blackmon; Brian A Bruckner; Michael J Reardon
Journal:  Ann Thorac Surg       Date:  2015-10-21       Impact factor: 4.330

Review 4.  Unusual primary tumors of the heart.

Authors:  T J Vander Salm
Journal:  Semin Thorac Cardiovasc Surg       Date:  2000-04

5.  Lyophilized bovine pericardium treated with a phenethylamine-diepoxide as an alternative to preventing calcification of cardiovascular bioprosthesis: preliminary calcification results.

Authors:  Cassiano G Aimoli; Grínia M Nogueira; Leandro S Nascimento; André Baceti; Adolfo A Leirner; Marina J S Maizato; Olga Z Higa; Bronislaw Polakiewicz; Ronaldo N M Pitombo; Marisa M Beppu
Journal:  Artif Organs       Date:  2007-04       Impact factor: 3.094

6.  Primary cardiac sarcoma.

Authors:  Maryam Hamidi; John S Moody; Tracey L Weigel; Kevin R Kozak
Journal:  Ann Thorac Surg       Date:  2010-07       Impact factor: 4.330

7.  Tumors of the heart. A 20-year experience with a review of 12,485 consecutive autopsies.

Authors:  K Y Lam; P Dickens; A C Chan
Journal:  Arch Pathol Lab Med       Date:  1993-10       Impact factor: 5.534

8.  Malignant primary cardiac tumors: review of a single institution experience.

Authors:  Lijo Simpson; Shaji K Kumar; Scott H Okuno; Hartzell V Schaff; Luis F Porrata; Jan C Buckner; Timothy J Moynihan
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

9.  Primary cardiac sarcomas: a clinicopathologic analysis of a series with follow-up information in 17 patients and emphasis on long-term survival.

Authors:  Paul J Zhang; John S Brooks; John R Goldblum; Brian Yoder; Raja Seethala; Bruce Pawel; Joseph H Gorman; Robert C Gorman; Jui-Han Huang; Michael Acker; Navneet Narula
Journal:  Hum Pathol       Date:  2008-07-07       Impact factor: 3.466

10.  Outcomes after surgical resection of cardiac sarcoma in the multimodality treatment era.

Authors:  Faisal G Bakaeen; Dawn E Jaroszewski; David C Rice; Garret L Walsh; Ara A Vaporciyan; Steven S Swisher; Robert Benjamin; Shanda Blackmon; Michael J Reardon
Journal:  J Thorac Cardiovasc Surg       Date:  2009-04-02       Impact factor: 5.209

View more
  5 in total

1.  A biologic scaffold-associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy.

Authors:  Matthew T Wolf; Sudipto Ganguly; Tony L Wang; Christopher W Anderson; Kaitlyn Sadtler; Radhika Narain; Christopher Cherry; Alexis J Parrillo; Benjamin V Park; Guannan Wang; Fan Pan; Saraswati Sukumar; Drew M Pardoll; Jennifer H Elisseeff
Journal:  Sci Transl Med       Date:  2019-01-30       Impact factor: 17.956

Review 2.  Utility of extracellular matrix powders in tissue engineering.

Authors:  Lauren Edgar; Afnan Altamimi; Marta García Sánchez; Riccardo Tamburrinia; Amish Asthana; Carlo Gazia; Giuseppe Orlando
Journal:  Organogenesis       Date:  2018-09-05       Impact factor: 2.316

3.  Outcomes and Predictors of Mortality After Mitral Valve Surgery in High-Risk Elderly Patients: The Heidelberg Experience.

Authors:  Sabreen Mkalaluh; Marcin Szczechowicz; Bashar Dib; Gabor Szabo; Matthias Karck; Alexander Weymann
Journal:  Med Sci Monit       Date:  2017-12-31

4.  Surgery for Cardiac Papillary Fibroelastoma: A 12-Year Single Institution Experience.

Authors:  Sabreen Mkalaluh; Marcin Szczechowicz; Saeed Torabi; Bashar Dib; Anton Sabashnikov; Ahmed Mashhour; Matthias Karck; Alexander Weymann
Journal:  Med Sci Monit Basic Res       Date:  2017-07-14

Review 5.  Research progress in decellularized extracellular matrix-derived hydrogels.

Authors:  Wenhui Zhang; Aoling Du; Shun Liu; Mingyue Lv; Shenghua Chen
Journal:  Regen Ther       Date:  2021-05-18       Impact factor: 3.419

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.